Tag: AMyris

Earnings season: An advanced bioecononomy’s health and wellness check-up

Earnings season: An advanced bioecononomy’s health and wellness check-up

August 14, 2017 |

In today’s Digest, let’s look at trends driving the industry’s results at scale — and while money is not the measure of all progress, it is the ultimate yardstick and especially for companies that have reached industrial scale. So, let’s look at Q2 earnings statements now just coming out from four of the sector’s signature […]

Read More

Amyris posts 168% increase in revenue for 2017 Q2 over 2016 Q2

Amyris posts 168% increase in revenue for 2017 Q2 over 2016 Q2

August 12, 2017 |

In California, Amyris announced its net income of $620,000 and total revenue of $25.7 million for the second quarter, which was good news for investors who saw a 168% increase over the same period last year. Product sales were up over 159% from last year’s Q2 as well, with Biossance sales delivering outstanding results and […]

Read More

Amyris closes second $25 million tranche of financing

Amyris closes second $25 million tranche of financing

August 10, 2017 |

In California, Amyris, Inc. announced the closing of the second and final tranche of its previously announced financing. The second tranche of $50 million in a private placement was led by a $25-million investment from Koninklijke DSM N.V. with the remaining $25 million contributed by Vivo Capital. “We are pleased to have the support of […]

Read More

Amyris enters first production development and production agreement with DSM

Amyris enters first production development and production agreement with DSM

July 17, 2017 |

In California, Amyris announce it has entered into its first product development and production agreement with Koninklijke DSM N.V. (Royal DSM), the global science-based company active in health, nutrition and materials, to develop a food and nutrition molecule for which DSM is a major market provider. As part of the previously announced equity investment DSM […]

Read More

Two Up: Amyris, Queensland gamble on farnesene for SE Asia

Two Up: Amyris, Queensland gamble on farnesene for SE Asia

June 22, 2017 |

  The Digest discovered this hand-written lyric, we think written with a thumbnail dipped in biocrude, near Amyris headquarters in Emeryville, California. Somewhere north of Byron Bay where Cooktown orchids grow, and cane is ever-present and the Pioneer River flows, there’ll be a group of smarties along the coastal towns hawking tonnes of bio farnesene for a zillion yuan a […]

Read More

Two Up: Amyris, Queensland gamble on farnesene for SE Asia

Two Up: Amyris, Queensland gamble on farnesene for SE Asia

June 22, 2017 |

  The Digest discovered this hand-written lyric, we think written with a thumbnail dipped in biocrude, near Amyris headquarters in Emeryville, California. Somewhere north of Byron Bay where Cooktown orchids grow, and cane is ever-present and the Pioneer River flows there’ll be a group of smarties along the coastal towns hawking tonnes of bio farnesene for a zillion yuan a […]

Read More

Amyris and Queensland team on commercial-scale biorefineries

Amyris and Queensland team on commercial-scale biorefineries

June 20, 2017 |

In Australia, Amyris, Inc. and the Government of Queensland announced the next step in their plans to develop a leading industrial biotechnology hub in Southeast Asia. Plans call for developing a new production plant with support from local partners to produce Amyris’s sugar cane-based ingredient called farnesene, which is used in products including cosmetic emollients, […]

Read More

T Minus 90. Amyris’ next 90 days will say much, and may say all

T Minus 90. Amyris’ next 90 days will say much, and may say all

May 21, 2017 |

Moving fast, but will escape velocity be reached? Amyris reports 164% product revenue jump — yet questions linger. In California, Amyris reported Q1 revenues of $13.0M compared with $8.8M for Q1 2016, and touted the “significant increase in product sales, primarily in the personal care and health and nutrition markets, offset by a slight decline […]

Read More

First $47 million investment tranche led by Royal DSM into Amyris closed

First $47 million investment tranche led by Royal DSM into Amyris closed

May 15, 2017 |

In California, Amyris, Inc. announced the closing of the first tranche of up to $95 million in planned equity financing that the company previously announced on May 8, 2017. The first tranche was approximately $47 million and was led by Koninklijke DSM N.V. (Royal DSM) with participation by qualified institutional buyers and accredited investors, including […]

Read More

Amyris says “double the revenue” in sight with Nenter Vitamin E Partnership as DSM Vitamin A partnership unveiled

Amyris says “double the revenue” in sight with Nenter Vitamin E Partnership as DSM Vitamin A partnership unveiled

May 11, 2017 |

In California, Amyris said it expects revenue related to its Vitamin E partnership with Nenter to more than double based on the current success of the program. During 2016, the company shipped approximately $9 million of farnesene to Nenter for conversion to Vitamin E and expects 2017 shipments to Nenter to be about $20 million. […]

Read More